TrialReader


Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source

NCT03224026 — Completed, 206 participants, MeMed Diagnostics Ltd.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Which Virus Leads to Viremia in Children With Fever Without Source and do New Biomarkers Correlate With Viral and Bacterial Infections?

RegistryNCT03224026
StatusCompleted
Study typeObservational
Enrollment206 (Actual)
SponsorMeMed Diagnostics Ltd. (Industry); collaborators: University Hospital, Geneva
ConditionsInfectious Disease, Fever, Viremia
Datesstart 2015-11-01, primary completion 2018-06-01, completion 2018-08-01, first posted 2017-07-21, last updated 2023-01-06
Locations1 site in Switzerland

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Infectious Disease All trials for Fever

-Summary

The study is an observational blinded Validation study in pediatric patients below 3 years old with a diagnosis of Fever Without Source (FWS). In this study the investigators aim to validate the performance of a proteomic signature aiding the physicians to discriminate between viral and bacterial infections in febrile children. The study will also assess the prevalence of Human Enteroviruses (HEV), Human Parechoviruses (HPeV), Adenovirus (AdV) and Human Herpesvirus type 6 (HHV-6) viremia, as well as Kingella Kingae bacteremia in the study cohort.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Fever Without SourceClinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
Healthy controlChildren visiting the hospital due to a non-infectious, non inflammatory etiology

+Outcome measures

Primary outcomes

  • Diagnostic accuracy compared to expert panel for bacterial versus viral. [0-7 days after initiation of symptoms]: Sensitivity, specificity, NPV and PPV were measured for ImmunoXpert and Labscore. The proteomic signature is a combination of different markers including: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (pg/mL), interferon γ-induced protein-10 (IP-10) (pg/mL) and C-reactive protein (CRP) (mg/L). The proteomic signature is expressed as a score (no units. ranges 0-100). The Labscore is a combination of procalcitonin (ng/mL), C-reactive protein (CRP) (mg/L) and urinary dipstix (positive if presence of leucocyturia or nitrites). The Lab-score is expressed as a score (no units. ranges 0-9)

Secondary outcomes

  • Diagnostic accuracy compared to microbiology gold standard for ruling out invasive bacterial infection. [0-7 days after initiation of symptoms]: Case by case comparison between microbiology gold standard and ImmunoXpert and Labscore. The proteomic signature is a combination of different markers including: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (pg/mL), interferon γ-induced protein-10 (IP-10) (pg/mL) and C-reactive protein (CRP) (mg/L). The proteomic signature is expressed as a score (no units, ranges 0-100). The Labscore is a combination of procalcitonin (ng/mL), C-reactive protein (CRP) (mg/L) and urinary dipstix (positive if presence of leucocyturia or nitrites). The Lab-score is expressed as a score (no units, ranges 0-9).
  • Comparison of biomarker levels in patients with different etiologies as classified by the expert panel or healthy. [0-7 days after initiation of symptoms in cases with infection.]: An expert panel classified a patient as experiencing a bacterial versus viral infection. In addition healthy patients were requited. The following biomarkers were examined across the healthy versus bacterial versus viral patients: 1. The proteomic signature is a combination of different markers including: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (pg/mL), interferon γ-induced protein-10 (IP-10) (pg/mL) and C-reactive protein (CRP) (mg/L). The proteomic signature is expressed as a score (no units, ranges 0-100). 2. The Labscore is a combination of procalcitonin (ng/mL), C-reactive protein (CRP) (mg/L) and urinary dipstix (positive if presence of leucocyturia or nitrites). The Lab-score is expressed as a score (no units, ranges 0-9). 3. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (pg/mL). 4. interferon γ-induced protein-10 (IP-10) (pg/mL). 5. C-reactive protein (CRP) (mg/L).
  • Prevalence of viruses in children with fever without source. [0-7 days after the initiation of symptoms]: Prevalence of Human Enteroviruses, Human Parechoviruses, Adenovirus and Human Herpesvirus type 6 viremia and viremia from other microorganism identified by Next-Generation Sequencing (NGS) (no units) or other techniques, as well as K. kingae bacteremia in children under three years old presenting with fever without source.

+Eligibility

Sex: All, ages: 1 Day to 3 Years, accepts healthy volunteers

Inclusion Criteria:

* Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history or the physical exam)
* Age < 3 years old
* Informed consent (IC) given by parent or legal guardian

Exclusion Criteria:

* Unavailable blood
* Comorbidities predisposing to infections such as cancer, primary or secondary immunodeficiency, and iatrogenic immunosuppression

Inclusion Criteria for healthy controls:

* Age < 3 years old
* Informed consent (IC) given by parent or legal guardian
* No suspicion of infectious or inflammatory disease at presentation and during the two weeks before.

+Locations (1)

FacilityCityCountryStatus
Geneva University HospitalsGenevaSwitzerland

+Publications

  • Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, Kriger O, Bamberger E, Fonar Y, Yacobov R, Wolchinsky R, Denkberg G, Dotan Y, Hochberg A, Reiter Y, Grupper M, Srugo I, Feigin P, Gorfine M, Chistyakov I, Dagan R, Klein A, Potasman I, Eden E. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One. 2015 Mar 18;10(3):e0120012. doi: 10.1371/journal.pone.0120012. eCollection 2015. PMID 25785720
  • Colvin JM, Muenzer JT, Jaffe DM, Smason A, Deych E, Shannon WD, Arens MQ, Buller RS, Lee WM, Weinstock EJ, Weinstock GM, Storch GA. Detection of viruses in young children with fever without an apparent source. Pediatrics. 2012 Dec;130(6):e1455-62. doi: 10.1542/peds.2012-1391. Epub 2012 Nov 5. PMID 23129086
  • Ambrosioni J, Bridevaux PO, Wagner G, Mamin A, Kaiser L. Epidemiology of viral respiratory infections in a tertiary care centre in the era of molecular diagnosis, Geneva, Switzerland, 2011-2012. Clin Microbiol Infect. 2014 Sep;20(9):O578-84. doi: 10.1111/1469-0691.12525. Epub 2014 Jan 24. PMID 24382326
  • Results publication: L'Huillier AG, Mardegan C, Cordey S, Luterbacher F, Papis S, Hugon F, Kaiser L, Gervaix A, Posfay-Barbe K, Galetto-Lacour A. Enterovirus, parechovirus, adenovirus and herpes virus type 6 viraemia in fever without source. Arch Dis Child. 2020 Feb;105(2):180-186. doi: 10.1136/archdischild-2019-317382. Epub 2019 Aug 28. PMID 31462437

My Notes